Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

Clinical trial NCT04869137 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04869137
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Merkel Cell Carcinoma Neuroendocrine Carcinoma of the Skin Trabecular Carcinoma of the Skin

Start date: 2021-05-28
Primary completion: 2025-09-13
Enrollment: 26

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.